Strides Arcolab Limited, one of India's largest exporters of branded generic pharmaceuticals, received a green signal from the World Health Organization for its anti-HIV drugs lamivudine and zidovidine recently. The company is among the list of pre-qualified suppliers of generic fixed dose combinations in the segment.

Prior to this approval, Strides had four HIV drugs in the WHO pre-qualified list. An additional three products have been submitted for pre-qualification, which will complete a comprehensive product offering from the company.

Strides Arcolab Limited, listed on the Bombay Stock Exchange Limited and National Stock Exchange of India Limited (STAR), has a global presence in more than 50 countries. The company has plants in India, USA, Poland, Italy, Brazil and Mexico. It is supplies pharmaceuticals to a number of geographic locations including Latin America, Europe, South East Asia, Africa and Australia, amongst other markets.

The Indian manufacturing facilities for the regulated markets are approved by all major regulatory bodies such as US FDA, MHRA, TGA and MCC.This broad manufacturing network facilitates partnering with global organizations ranging from UNICEFand WHO-Global Drug Facility to European and American pharmaceutical multinationals and also private labelers and distribution chains.

Further, the company has product registrations in over 37 countries and has earned ISO 9001, ISO 14001 accreditations. The company production capability encompasses formulations in various dosage forms, including capsules, tablets, liquid injectables and is one of the world's top five manufacturers of softgel capsules. Strides employs approximately 1,300 people across the globe.